A wide array of testing options are available for characterizing both solid and hematopoietic tumors including cytogenetic assays for the detection of copy number and structural alterations as well as sequencing assays for the detection of somatic mutations or fusion events. In addition, a testing protocol for hematopoietic tumors is offered which ensures proper selection of molecular assays for each sample based on review by an expert hematopathologist. Details and complete testing menus are available below.
- Hematopathology Protocol
For diagnosis of suspected hematopoietic tumors or monitoring of an established diagnosis, the Hematopathology Protocol (for bone marrow or tissue samples) and the Path Review with Reflex Flow Cytometry and Genomics (for peripheral blood samples) allows an expert hematopathologist to first review the sample morphology and then, following analysis by flow cytometry and other techniques as appropriate, the hematopathologist will order any additional molecular or cytogenetic testing that is indicated for diagnosis confirmation, risk stratification, or targeted treatment selection. Utilizing the these order options ensures that molecular and cytogenetic assays are initiated efficiently and effectively and eliminates the need for the clinical team to decide on ancillary testing before the lineage or degree of disease involvement is known.
- Cytogenetic Testing
Karyotyping and fluorescence in situ hybridization techniques are available for chromosome analysis of both hematopoietic and select solid tumors. Details of available FISH probes and panels as well as specimens accepted can be found here:
- Targeted Oncology Testing
Using various techniques, including qPCR and Next Generation Sequencing (NGS), several single-gene targeted mutation assays, single fusion detection assays, and larger targeted mutation and fusion panels are available to characterize both hematopoietic and solid tumors, including high-sensitivity assays for the detection of measurable (minimal) residual disease in select cases of AML.
Selected Assay Details: